300,000+ clinical trials. Find the right one.

221 active trials for Neoplasms

Parenteral Nutrition Therapy in Patients With Incurable Cancer

Parenteral nutrition (PN) treatment in patients with incurable cancer is understudied and the level of evidence for clinical meaningful effects is weak. The ESPEN guidelines give few specific recommendations regarding which patients with incurable cancer that should be offered PN treatment. According to the Norwegian prescription database, the use of parenteral nutrition has more than doubled in the period 2004-2015. These numbers do not separate between diagnoses and medical conditions, so the current use of medical nutrition in cancer patients in Norway is not known. The decision to initiate parenteral nutrition is taken at hospitals, whereupon the patient returns home to their respective municipalities and receives follow-up by the home care service. There are often uncertainties about the duration of treatment, as patients' clinical condition can change rapidly. One major challenge health care professionals face is to decide when to end medical nutrition therapy. Patients and relatives may experience fear that discontinuation of medical nutrition accelerates death, while health care professionals often experience that nutrition in many cases does not help and inflicts negatively on patients' condition. This makes communication concerning end of nutritional treatment between health care professionals at several health care levels, patients and their relatives challenging. There is a need for a stronger evidence base considering the effect of medical nutrition in patients with incurable cancer. To be able to study the effect of PN treatment, more studies on clinical practice of PN treatment to patients with incurable cancer is needed. Aspects like indication for use, dosage and duration of PN treatment is poorly described in the available literature. Thus, the aim of this study is to describe indications for use of PN, duration of treatment, reasons for discontinuation, method of administration, possible benefits and complications as well as survival.

Start: November 2018
Machine Learning to Analyze Facial Imaging, Voice and Spoken Language for the Capture and Classification of Cancer/Tumor Pain

Background: Cancer pain can have a very negative effect on people s daily lives. Researchers want to use machine learning to detect facial expressions and voice signals. They want to help people with cancer by creating a model to measure pain. They want the model to reflect diverse faces and facial expressions. Objective: To find out whether facial recognition technology can be used to classify pain in a diverse set of people with cancer. Also, to find out whether voice recognition technology can be used to assess pain. Eligibility: People ages 12 and older who are undergoing treatment for cancer Design: Participants will be screened with: Cancer history Information about their gender and skin type Information about their access to a smart phone and wireless internet Questions about their cancer pain Participants will have check-ins at the clinic and at home. These will occur over about 3 months. They will have 2-4 check-ins at the clinic. They will check in at home about 3 times per week. During check-ins, participants will answer questions and talk about their cancer pain. They will use a mobile phone or a computer with a camera and microphone to complete a questionnaire. They will record a video of themselves reading a 15-second passage of text and responding to a question. During the clinic check-ins, professional lighting, video equipment, and cameras will be used for the recordings. During remote check-ins, participants will be asked to complete the questionnaire and recordings alone. They should be in a quiet and bright room. The room should have a white wall or background.

Start: October 2020
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab)

This study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours). The second part is open to people with specific types of advanced lung cancer, skin cancer, sarcoma, liposarcoma, and liver cancer. The participants get a combination of 3 medicines called BI 907828, BI 754091, and BI 754111. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. BI 754091 and BI 754111 are antibodies that may help the immune system fight cancer (immune checkpoint inhibitors). The purpose of the first part of the study is to find out the highest dose of BI 907828 that the participants can tolerate in combination with BI 754091 and BI 754111. Once the best dose of BI 907828 for the combination with BI 754091 and BI 744111 is found, it will be used in the second part of the study. The purpose of the second part is to see whether the combination of BI 907828 with BI 754091 and BI 744111 is able to make tumours shrink. Some participants in the second part get combinations of 2 instead of 3 medicines: BI 754091 and BI 754111 or BI 754091 and BI 907828. The participants are in the study as long as they benefit from and can tolerate treatment. During this time, they get infusions of BI 754091 and BI 754111, and take tablets with BI 907828 every 3 weeks. The doctors check how many participants have health problems during the study. The doctors also monitor the size of the tumour.

Start: June 2019